A comprehensive study of safety evaluation for novel bispecific antibodies combined with chemotherapy in cancer

Int J Surg. 2024 Aug 1;110(8):5312-5316. doi: 10.1097/JS9.0000000000001602.

Authors

Guo Lin^{1

2}, Xu Sun³, Kai Kang^{1

2}, Ailin Zhao³, Yijun Wu^{1

2}

Affiliations

¹ Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University.
² Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University.
³ Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Bispecific* / administration & dosage
Antibodies, Bispecific* / adverse effects
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Humans
Neoplasms* / drug therapy

Substances

Antibodies, Bispecific
Antineoplastic Agents